Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research cut shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a hold rating to a sell rating in a research report released on Friday morning.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other brokerages have also recently issued reports on DRNA. HC Wainwright reissued a buy rating and set a $10.00 price objective (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. ValuEngine raised shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, February 2nd. BidaskClub raised shares of Dicerna Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, January 25th. SunTrust Banks started coverage on shares of Dicerna Pharmaceuticals in a research note on Monday, February 5th. They set a buy rating and a $13.00 price objective for the company. Finally, Chardan Capital reissued a neutral rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Dicerna Pharmaceuticals has an average rating of Hold and a consensus target price of $10.05.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was purchased at an average cost of $7.00 per share, with a total value of $1,995,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 29.41% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp boosted its position in Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares during the period. Birchview Capital LP boosted its position in Dicerna Pharmaceuticals by 125.0% during the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 25,000 shares during the period. Emerald Advisers Inc. PA purchased a new stake in Dicerna Pharmaceuticals during the 4th quarter worth $266,000. Deschutes Portfolio Strategy LLC purchased a new stake in Dicerna Pharmaceuticals during the 3rd quarter worth $575,000. Finally, Vanguard Group Inc. boosted its position in Dicerna Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the period. 23.86% of the stock is owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.